DOSING

Recommended dosing

Image

Treatment with BRAFTOVI^® + MEKTOVI^® should be continued until the patient no longer derives benefit or the development of unacceptable toxicity.

^a For patients with mild hepatic impairment, administration of BRAFTOVI should be undertaken with caution at a reduced dose. In the absence of clinical data, BRAFTOVI is not recommended in patients with moderate to severe hepatic impairment.¹

Adapted administration methods for patients unable to swallow^1,2

BRAFTOVI 75 mg and 50 mg capsules^a,b 

May be opened and the content dispersed in a small quantity (~20 mL) of apple sauce and taken immediately¹

Image

MEKTOVI 15 mg tablets only^c

May be dispersed in a small glass (~10 mL) of either water, orange juice or apple juice and taken immediately² 

The glass should be rinsed with ~10 mL of water, orange juice or apple juice, and content drunk immediately²

Image

For complete information, please refer to the Summaries of Product Characteristics. 

a The recommended dose of BRAFTOVI® is 450 mg (six 75 mg capsules) once daily, when used in combination with binimetinib^.1 

b BRAFTOVI® 50 mg capsules only indicated for patients with melanoma undergoing dose reductions.¹ 

c The recommended dose of MEKTOVI® is 45 mg twice daily approximately 12 hours apart, corresponding to a total daily dose of 90 mg. Only MEKTOVI® 15 mg tablets may be dispersed in liquid.²

Patient monitoring is recommended prior, during and after the treatment. For more information on safety, explore our Therapy Management Guide, on the Support and Resources page.

GO TO SUPPORT AND RESOURCES

Recommended dose adjustments

BRAFTOVI^® + MEKTOVI^® are indicated to be taken in combination.

The management of ARs may require dose reduction, temporary interruption, or treatment discontinuation.

Image

Dose modifications are recommended to manage certain adverse reactions.

_{Please see Section 4.2 of the full Summaries of Product Characteristics for additional information.}

^aThere are limited data for dose reduction to 100 mg QD. If unable to tolerate 100 mg QD, permanently discontinue BRAFTOVI.^1
bIf unable to tolerate 30 mg BID, permanently discontinue MEKTOVI.¹ 

BID, twice daily; QD, once daily. 

Dose interruption and discontinuation

When temporarily interrupting or permanently discontinuating BRAFTOVI or MEKTOVI, please adapt the other drug's posology according to the table below.

Image

For complete information, please refer to the Summaries of Product Characteristics.